保尔佳治疗晚期恶性肿瘤的临床观察

将76例晚期恶性肿瘤患者随机等分为2组：单纯化疗组及化疗加用保尔佳治疗组，以观察保尔佳的临床作用。结果：保尔佳治疗组有效率42．1％，体力状况改善老39．5％，外周血白细胞数正常者73．7％，均显著高于化疗组（分别为21．1％、15.7％和44．7％；P＜0．05、P＜0．025和P＜0．025）；毒副反应两组无显著性差异。提示保尔佳与化疗药物联合应用治疗晚期恶性肿瘤优于单纯化疗，并能改善患者的体力状况，减轻化疗所致的外周血白细胞数下降。

CLINICAL OBSERVATION OF POLYERGA IN THE PATIENTS WITH ADVANCED MALIGNANT TUMORS

In order to observe the clinical effects of polyerga, two groups were studied in a randomized crossover trial in 76 patients with advanced malignant tumors. Of them 38 patients were treated with usual chemotherapeutic regimens and the others received both polyerga and chemotherapy at the same time. Results showed that the response rate (42. 1 %), performance status improvement (39. 5%) and peripheral blood WBC counts (73. 7%) in normal range in the polyerga group were remarkably higher than those in the chemotherapuetic group (21.1 %, 15. 7% and 44. 7%, P＜0. 05, P＜0. 025 and P＜0. 025); The toxicities, such as nausea and vomiting, fever, hepatic and renal function damage, were no significant differences between the two groups. The results suggest that polyerga, combined with anticancer drugs in treating the patients with advanced malignant tumors is superior to simple chemotherapy,improves patients' performance status and relieves the decrease of peripheral blood WBC counts in duced by chemotherapy.